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TEL/ETV6 is the first transcription factor identified that is specifically required for hematopoiesis within the bone marrow. This
gene has been found to have multiple fusion partners; 35 different chromosome bands have been involved in ETV6
translocations, of which 13 have been cloned. To identify additional ETV6 partner genes and to characterize the chromosomal
abnormalities more fully, we studied bone marrow samples from patients known to have rearrangements of 12p, using
fluorescence in situ hybridization (FISH) and spectral karyotyping (SKY). FISH analysis was done with 14 probes located on
12p12.1 to 12p13.3. Nine ETV6 rearrangements were identified using FISH. The aberrations include t(1;12)(p36;p13),
t(4;12)(q12;p13) (two patients), t(4;12)(q22;p13), t(6;12)(p21;p13), der(6)t(6;21)(q15;q?)t(12;21)(p13;q22), t(6;12)(q25;p13),
inv(12)(p13q24), and t(2;2;5;12;17)(p25;q23;q31;p13;q12). Six new ETV6 partner bands were identified: 1p36, 4q22, 6p21,
6q25, 12q24, and 17q12. Our present data as well as previous data from us and from other researchers suggest that ETV6 is
involved in 41 translocations. The breakpoints in ETV6 were upstream from the exons coding for the HLH (helix-loop-helix)
domain in six cases. Although cytogenetic analysis identified 12p abnormalities in all cases, FISH and SKY detected new and
unexpected chromosomal rearrangements in many of them. Thus, complete characterization of the samples was achieved by
using all three techniques in combination. © 2001 Wiley-Liss, Inc.
INTRODUCTION
TEL (translocation–E26 transformation-specific–
leukemia), also called ETV6, is the first transcrip-
tion factor identified that is required specifically for
hematopoiesis within the bone marrow (Wang et
al., 1998). This gene frequently is rearranged in
translocations in a wide spectrum of human leuke-
mias (Mitelman, 1998), with the same fusion tran-
script in both myeloid and lymphoid leukemias
(Peeters et al., 1997a). ETV6 has been found to
have many fusion partners. Using fluorescence in
situ hybridization (FISH), 35 different chromo-
some bands have been shown to be involved in
ETV6 translocations, of which 13 have been cloned:
ARNT (1q21), ARG (1q25), MDS1/EVI1 (3q26),
CHIC2/BTL (4q12), ASC2 (5q13), PDGFRB (5q33),
STL (6q23), JAK2 (9p24), ABL (9q34), CDX2
(13q12), TRKC (15q25), CBFA2 (21q22), and MN1
(22q11) (Golub et al., 1994, 1995; Romana et al.,
1995; Buijs et al., 1995; Papadopoulos et al., 1995;
Peeters et al., 1997a,b; Suto et al., 1997; Cazzaniga
et al., 1999; Chase et al., 1999; Cools et al., 1999;
Eguchi et al., 1999; Yagasaki et al., 1999; Iijima et
al., 2000; Salomon-Nguyen et al., 2000). The ETV6
protein contains two critical domains, the 59 helix-
loop-helix (HLH) dimerization domain (coded for
by exons 3 and 4) and the 39 E26 transformation-
specific (ETS) DNA-binding domain (exons 6 to
8). Little is known about the function of the central
region of ETV6. The translocation breakpoints are
distributed throughout the gene, and ETV6 con-
tributes to the pathogenesis of leukemia by re-
markably diverse molecular mechanisms that are
only partially understood.
To identify additional ETV6 partner genes and
to characterize the chromosomal abnormalities
more fully, we studied bone marrow samples from
patients known to have rearrangements of 12p,
using three different techniques: G-banding,
FISH, and spectral karyotyping (SKY). Nine pa-
tients with ETV6 rearrangements were identified
by FISH. Although cytogenetic analysis pin-
pointed 12p abnormalities in all cases, FISH and
Supported by: Departamento de Salud del Gobierno de Navarra;
Fundacion Empresa-Universidad de Navarra; National Cancer In-
stitute; Grant number: CA42557; G. Harold and Leila Y. Mathers
Charitable Foundation; Spastic Paralysis Foundation; Illinois-East-
ern Iowa District of Kiwanis International.
*Correspondence to: Marı´a D. Odero, M.D., Ph.D., Department
of Genetics, University of Navarra, C/Irunlarrea s/n, 31008-Pam-
plona, Spain. E-mail: modero@unav.es
Received 11 September 2000; Accepted 7 November 2000
Published online 30 March 2001
GENES, CHROMOSOMES & CANCER 31:134–142 (2001)
© 2001 Wiley-Liss, Inc.
SKY detected new chromosomal rearrangements in
many of them.
MATERIALS AND METHODS
Patients
Fifteen patients with hematologic malignancies
and 12p balanced translocations or add(12p) stud-
ied at the University of Chicago (U.S.A.) and at the
University of Navarra (Spain) were included in the
present report. Of these patients, four were studied
at diagnosis and 11 at relapse. All samples were
obtained with informed consent.
Fluorescence In Situ Hybridization
Cytogenetic studies were done on unstimulated
short-term bone marrow cultures. G-banded karyo-
types were described according to the ISCN (Mitel-
man, 1995). FISH analysis was done using 11 cosmid
and three phage probes located on 12p12.1 to
12p13.3. TEL/ETV6 was analyzed by 179A6 (exon 1),
50F4 (exon 2), 54D5 (exons 5–8), and 148B6 (exon 8)
(all kindly provided by Dr. Peter Marynen, Center for
Human Genetics, University of Leuven, Leuven,
Belgium) and by a cosmid contig that contained
about 60 kb of genomic sequences surrounding exon
3 (TEL 11/18). Two 90-kb P1 phage clones that
contained KIP1/CDKNIB were used to analyze this
gene (Pietenpol et al., 1995) (addresses: 2096 and
2097; Genome Systems, Inc). The order of these
probes was telomere-D12S235-D12S237-Phage
L24A-D12S229-HTY3049c17-D12S133-179A6-50-
F4-TEL11/18-54D5-148B6-P12096-P12097-D12-
S119-D12S20-centromere (Kobayashi et al., 1994;
Baens et al., 1996). Three PACs assigned to 4q11-q12
(238H24, 200D9, and 1146G14) (provided by Dr.
Peter Marynen, Center for Human Genetics, Univer-
sity of Leuven, Leuven, Belgium) were used to
check the involvement of CHIC2/BTL in cases with
t(4;12).
Additional FISH experiments were performed us-
ing whole-chromosome painting probes (WCP) for
chromosomes 6, 7, 11, 12, and 13, or centromere-
specific probes (CEP) direct labeled with Spectrum
Greent or Spectrum Oranget-dUTP (Vysis, Down-
ers Grove, IL). In case 8, we used the LSI TEL-
AML1 probe to determine whether CBFA2/AML1
was involved (Vysis). The probes were labeled
with biotin-11-dUTP or digoxigenin-11-dUTP
(Boehringer-Mannheim, Indianapolis, IN) using
nick translation and were hybridized to the pa-
tients’ slides as previously described (Rowley,
1990). The biotin-labeled probes were detected
with fluorescein isothiocyanate (FITC)– conju-
gated avidin. The digoxigenin-labeled probes
were detected with rhodamine-conjugated sheep
anti-digoxigenin antibodies (Boehringer-Mann-
heim). Chromosomes were identified using coun-
terstaining with 496-diamidino-2-phenylindole
dihydrochloride (DAPI). The presence or ab-
sence of the FISH signals was scored on an
average of 12 abnormal metaphase cells (range,
7–20) per probe per patient. Images of the hy-
bridized cells were captured with a liquid-
cooled, charge-coupled device camera (Photo-
metrics, Tucson, AZ). Separate gray-scale images
for the DAPI and the FITC fluorescence were
acquired. The images were merged using Adobe
Photoshop (Adobe Systems Inc, San Jose, CA) on
a Macintosh computer (Apple Computers, Cu-
pertino, CA).
Spectral Karyotyping Analysis
The SKY probe mixture and hybridization re-
agents were obtained from Applied Spectral Imag-
ing (Carlsbad, CA). Slides for spectral karyotyping
were hybridized with the probe cocktail as previ-
ously described (Rowley et al., 1999) for 2 days at
37°C. For each case, between six and 12 metaphase
cells were captured and analyzed, using the SD200
system (Applied Spectral Imaging). Cases with
questionable or not obvious chromosome rear-
rangements were analyzed further using the appro-
priate painting or centromere-specific probes (Vy-
sis).
RESULTS AND DISCUSSION
Nine of the 15 patients with 12p balanced translo-
cations (60%) had rearrangements of the ETV6 gene.
These patients had various hematologic malignan-
cies, including four cases of acute myeloid leukemia
(AML), three of myelodysplastic syndromes (MDS),
one of acute lymphoblastic leukemia (ALL), and one
of chronic lymphocytic leukemia. The 12p aberra-
tions were the sole abnormality only in case 2. Eight
12p translocations affecting the ETV6 gene were
identified. The aberrations included t(1;12)(p36;p13),
t(4;12)(q12;p13) (two patients), t(4;12)(q22;p13), t(6;
12)(p21;p13), der(6)t(6;21)(q15;q?)t(12;21)(p13;q22),
t(6;12)(q25;p13), inv(12)(p13q24), and t(2;2;5;12;
17)(p25;q23;q31;p13;q12) (Table 1). Six new partner
bands were identified: 1p36, 4q22, 6p21, 6q25, 12q24,
and 17q12. FISH results are summarized in Table 2.
Although some of these abnormalities had been de-
tected previously using G-banding, this is the first
study reporting ETV6 involvement in these rear-
rangements.
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In addition to confirming the FISH results, SKY
allowed for the complete characterization of the
karyotype of the leukemia samples. In cases 5, 8,
and 9, additional FISH experiments were per-
formed using chromosome painting and centro-
mere probes to confirm complex translocations.
The revised karyotypes summarizing the G-band-
ing, FISH, and SKY results are shown in Table 1.
FISH and SKY confirmed the G-banding results in
cases 1, 2, and 3. The t(4;12) found in cases 2
(AML-M2) and 3 (AML-M0) seems to be the same
translocation reported by Cools et al. (1999) that
Figure 1. Diagram of the ETV6 gene showing the exons (numbered rectangles) and the protein domains.
The location of the breakpoints in patients in this report are above the line; the location of the breakpoints
in ETV6 in the cloned translocations already published is shown below the line.
TABLE 2. Results of FISH Analysis with ETV6 Specific Cosmid Probes*
Case 1
t(4;12)
(q22;p13)
Case 2
t(4;12)
(q12;p13)
Case 3
t(4;12)
(q12;p13)
Case 4
inv(12)
(p13q24)
Case 5 t(2;2;
5;12;17)
(p25;q23;q31;
p13;q12)
Case 6
t(1;12)
(p36;p13)
Case 7
t(6;12)
(q25;p13)
der(6)t(6;12)
Case 8
der(6)t(6;21)
(q15;q22)
t(12;21)
(p13;q22),
t(12;21)
Case 9
t(6;12)
(p21;p13)
179A6 (exon 1) der(4) der(4) der(4) 12q der(17) der(1) der(6)x2
der(6)x2,
der(21) der(6)
50F4 (exon 2) der(4) der(4) der(4) 12q der(17) der(1) der(6)x2
der(6)x2,
der(21) der(12)
TEL11/18 (exon 3) der(4) der(12) der(12) 12p der(12) der(12) der(6)x2
der(6)x2
der(21) der(12)
54D5 (exons 5–8) der(12) der(12) der(12) 12p der(12) der(12) der(12)
der(6)x2
der(21)
der(12) der(12)
148B6 (exon 8) der(12) der(12) der(12) 12p der(12) der(12) der(12) der(12) der(12)
*FISH, fluorescence in situ hybridization.
The chromosome location of TEL translocation is indicated in bold type.
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fuses ETV6 and CHIC2/BTL. In both cases the
breakpoint was in intron 2 of ETV6 (Fig. 2), up-
stream from the exons coding for the HLH do-
main, and in intron 3 of CHIC2/BTL. Only four
other cases with this rearrangement have been re-
ported: three were classified as AML-M0 and one
as myeloid/natural killer (NK) cell leukemia (Cools
et al., 1999). Although more FISH studies are re-
quired to confirm the involvement of these genes
in cases with t(4;12), the CHIC2-BTL-ETV6 fusion
gene could be specific for an early hematopoietic
cell phenotype in AML.
Our case 2 seems to be similar to case 4 de-
scribed by Cools et al. (1999). The breakpoint in
ETV6 is between exon 2 and 3 in both cases, and
we were unable to detect a CHIC2-BTL-ETV6 fu-
sion transcript in the RNA of the patient (data not
shown). In case 1, the breakpoint in chromosome 4
was on 4q22, and FISH confirmed that it was telo-
meric to CHIC2/BTL. In cases 4 and 6, the trans-
location of 12p13 with an unknown chromosome
resulted in an inv(12)(p13q24) (Fig. 2) and a t(1;
12)(p36;p13). The breakpoint was between exons 2
and 3 in both cases. Identification of the new fusion
partner genes is in progress. There are several can-
didate genes on 1p36. Among the candidate genes
on 12q24 are PRKAB1 (protein kinase, AMP-acti-
vated, beta 1 non-catalytic subunit) and CIT.
In three cases, additional studies using FISH
and SKY resulted in a deletion 6 identified by
G-banding, which is more accurately described as a
translocation with chromosome 12: t(6;12) (cases 7
and 9) and der(6)t(6;21)t(12;21) (case 8). The
breakpoints in chromosome 6 were different, and
we could not identify a recurring rearrangement.
Duplication of the abnormal 6 was found in cases 7
and 8 (Table 1). Case 8 represents a 6-year-old girl
with ALL. Both chromosomes 12 were abnormal.
G-banding detected a der(12)t(12;17), and FISH
and SKY completed the analysis, showing that
the patient had the classic t(12;21), with an
ETV6-CBFA2 fusion confirmed by FISH. Sur-
prisingly, in addition to the normal chromosome
6, two der(6) with a complex der(6)t(6;21)t(12;
21) were detected (Fig. 3). ETV6 was deleted in
the der(12)t(12;17).
Figure 2. Examples of fluorescence in situ hybridization analysis of ETV6 rearrangements. A: Patient 2
with a t(4;12)(q12;p13). The red and green signals both label the normal 12p, whereas the green signal
representing the telomeric probe is translocated to the der(4) and the red centromeric probe labels the
der(12) chromosome. B: Patient 4 with inv(12)(p13q24). The red and green signals are together on the
normal 12p, and they are separated on the inv(12), with exon 8 remaining on 12p and exon 1 labeling 12q.
Figure 3. Examples of the analysis of cells from two patients. A:
Patient 8. Fluorescence in situ hybridization and spectral karyotyping
analysis showing the classic ETV6-CBFA2 fusion on the der(21) and two
der(6)t(6;21)t(12;21). In the upper left panel, the AML1 probe (red)
from chromosome 21 labels the der(21), both der(6) chromosomes,
and the der(12). There is no normal chromosome 21. The ETV6 probe
(green) labels the der(21) and both der(6) chromosomes; it is deleted
from the der(12). There is no normal chromosome 12. The upper right
panel shows with the CEP6 probe (red) that there is one normal 6 and
two der(6) chromosomes. The painting probe for chromosome 12
(green) labels both der(6), one der(21), the der(12)t(12;17), and the
der(12)t(12;21) chromosomes. Bottom SKY classified image shows
involvement of chromosomes 6, 12, and 21 in a complex rearrange-
ment. B: The lower set of images represent SKY analysis of patient 5.
Reverse 496-diamidino-2-phenylindole dihydrochloride (DAPI), spectral,
and classified images are shown. The reverse DAPI image is at bottom left,
the spectral image is in the upper left, and the classified image is in the upper
right. The abnormal chromosomes are identified with arrows. The karyo-
type using the classified image is shown in the lower right.
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Figure 3.
Another complex translocation t(2;2;5;12;17) in-
volving ETV6 was detected in a patient diagnosed
as having MDS refractory anemia with excess
blasts (RAEB) (case 5). FISH with ETV6 cosmids
showed that this gene was involved, with the
breakpoint between exons 2 and 3 (Table 2). The
partner bands were 5q31 and 17q12. The ETV6
partner gene on 5q31 could be ACS2 (Yagasaki et
al., 1999). This is the first time that band 17q12 has
been reported to be involved in rearrangements
with ETV6. SKY confirmed the translocation and
identified the add(5) as a der(5)t(2;5) (Fig. 3). The
partial loss of chromosome 5 material seen in this
patient is a recurrent event in cases of myeloid
disorders. The fact that ETV6 rearrangements oc-
curred as subclones in two cases (cases 1 and 5)
suggests that these ETV6 translocations could be
secondary abnormalities in myeloid malignancies.
FISH analysis with the other probes located on
12p12.1 to 12p13.3 showed no 12p deletions in
these cases.
The breakpoints in ETV6 in our cases were be-
tween exons 1 and 2 (one case) and exons 2 and 3
(five cases), upstream from the exons coding for the
TABLE 3. Review of the Literature of the Cases Reported With Reciprocal Translocations Involving ETV6*
TEL band partner Diagnosis Referencea
1p36 MDS Odero et al. (2001)
1q21 (ARNT) AML Berger et al. (1997), Salomon-Nguyen et al. (2000)
1q25 (ARG) AML Sato et al. (1997), Cazzaniga et al. (1999)
2q31 NHL-B Kobayashi et al. (1994)
3q26 (EVI1) AML, MDS Raynaud et al. (1996), Peeters et al. (1997b), Streubel et al. (1998)
4q12 (CHIC2/BTL) AML Andreasson et al. (1998), Cools et al. (1999)
4q22 AML Odero et al. (2001)
5q13 AML, ALL Kobayashi et al. (1994)
5q31 (ACS2) CML Wlodarska et al. (1997), Yagasaki et al. (1999)
5q33 (PDGFRb) AML, MDS Golub et al. (1994), Ho¨glund et al. (1996), Sato et al. (1997)
6p11-p12 MDS Streubel et al. (1998)
6p21 CLL Odero et al. (2001)
6p2?5 ALL Kobayashi et al. (1994)
6q21 ALL Raimondi et al. (1997)
6q23 (STL) ALL Suto et al. (1997)
6q25 MDS Odero et al. (2001)
7p12 ALL Wlodarska et al. (1998)
7p15 AML Wlodarska et al. (1998)
7q22 MDS Tosi et al. (1998)
7q32 AML Satake et al. (1999)
7q36 AML Tosi et al. (1998), Wlodarska et al. (1998), Slater et al. (1999), Tosi et al. (2000)
8p21 ALL Raimondi et al. (1997)
8q11 MDS Kobayashi et al. (1994)
9p24 (JAK2) ALL, CML Berger et al. (1997), Peeters et al. (1997a)
9q11 ALL Tosi et al. (1998)
9q34 (ABL) ALL, CML, AUL Kobayashi et al. (1994), Papadopoulos et al. (1995), Andreasson et al. (1997)
11q2? AML Andreasson et al. (1998)
12q24 AML Odero et al. (2001)
13q12 (CDX2) AML, ALL Streubel et al. (1998), Tosi et al. (1998), Wlodarska et al. (1998), Chase et al. (1999)
14q22 AUL Kobayashi et al. (1994)
15q25 (TRKC) AML Eguchi et al. (1999)
16q24 MDS Sato et al. (1997)
17p13 AML, MDS Kobayashi et al. (1994)
17q12 MDS Odero et al. (2001)
17q25 AML Wlodarska et al. (1998)
19q13 CML Kobayashi et al. (1994)
21q22 (AML1) AML Golub et al. (1995), Romana et al. (1995)
22q11 (MN1) AML Buijs et al. (1995)
22q12 AML Ho¨glund et al. (1996)
22q13.1 AML Kobayashi et al. (1994)
Xq28 MDS Berger et al. (1997)
*MDS, myelodysplastic syndromes; AML, acute myeloid leukemia; NHL-B, non-Hodgkin lymphoma, B cell; ALL, acute lymphoblastic leukemia; CML,
chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; AUL, acute undifferentiated leukemia.
aCloned ETV6 band partners are highlighted in bold type.
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HLH domain, and between exons 3 and 5 (two
cases) and exons 5 and 8 (one case) (Table 2 and
Fig. 1). In three patients (cases 2, 3, and 6), the
location of the breakpoint was confirmed by se-
quencing (data not shown). It is difficult to predict
the molecular consequences of these rearrange-
ments, owing to the variety of mechanisms de-
scribed in the 13 fusion genes cloned (Golub et al.,
1994, 1995; Romana et al., 1995; Buijs et al., 1995;
Papadopoulos et al., 1995; Peeters et al., 1997a,b;
Suto et al., 1997; Cazzaniga et al., 1999; Chase et
al., 1999; Cools et al., 1999; Eguchi et al., 1999;
Yagasaki et al., 1999; Iijima et al., 2000; Salomon-
Nguyen et al., 2000). In the six cases in which the
12p13 breakpoint occurred upstream from the ex-
ons coding for the HLH domain, in intron 1 or 2,
the oncogenic potential of some of these transloca-
tions could result from the ETV6 promoter’s driv-
ing the transcription of the partner gene, as has
been suggested for the ETV6-MDS1/EVI1 fusion
(Peeters et al., 1997b). The importance of the
ETV6 gene in hematopoiesis makes these results
interesting for future studies. Identification of
some of the new fusion partner genes is in progress.
Although the same fusion transcript has been
found in the translocations involving ETV6 in both
myeloid and lymphoid leukemias (Peeters et al.,
1997a), all the cases that have been cloned with
breakpoints between exons 2 and 4 are myeloid
neoplasias (Buijs et al., 1995; Peeters et al.,
1997a,b; Chase et al., 1999). In our series, the
breakpoints of the cases of myeloid malignancies
were between exons 2 and 5, whereas they were
outside this region in the two lymphoid cases (Ta-
ble 2). ETV6 and MLL are unique in having more
than 40 partner genes involved in translocations
leading to fusion genes. Our present data, along
with other of our data and the data of other re-
searchers, suggest that ETV6 is involved in 41
translocations (Table 3).
By combining G-banding, FISH, and SKY anal-
ysis, we redefined the aberrations described by
G-banding. FISH allowed the identification of six
new ETV6 translocations. In all instances, the
breakpoints of chromosomal rearrangements were
identified by comparing the banding and painting
patterns, but SKY confirmed the FISH findings
and clarified the abnormalities in two patients with
complex karyotypes. This approach allowed the
identification of hidden translocations in six cases.
Thus, complete characterization of the samples
was achieved by using all three techniques in com-
bination.
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